Phase 3 Recruiting NIH
This phase III trial tests whether adding trastuzumab and hyaluronidase-oysk (Herceptin Hylecta \[TM\]) or pertuzumab, trastuzumab and hyaluronidase-zzxf (Phesgo \[TM\]) to the usual chemotherapy (paclitaxel and carboplatin) works to shrin…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05256225
Sites in South Dakota: - Avera Cancer Institute-Aberdeen — Aberdeen, South Dakota
- Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This is a Phase III, 2-arm, randomized, open label, multicenter, global study assessing the efficacy and safety of puxitatug samrotecan compared to physician's choice of chemotherapy (doxorubicin or paclitaxel) in participants with B7-H4 s…
Sponsor: AstraZeneca
NCT ID: NCT07044336
Sites in South Dakota: - Research Site — Sioux Falls, South Dakota
- Research Site — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
DESTINY-Endometrial01 will investigate the efficacy of first-line T-DXd + rilvegostomig (Arm A) and/or T-DXd+ pembrolizumab (Arm B) when compared to chemotherapy (carboplatin + paclitaxel) + pembrolizumab (Arm C), by assessment of progress…
Sponsor: AstraZeneca
NCT ID: NCT06989112
Sites in South Dakota: - Research Site — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
The study is divided into two cohorts (Cohort 1 and Cohort 2), to which participants will be enrolled based on the amount of human epidermal growth factor receptor 2 (HER2) in their tumor sample. In Cohort 1, the main goal is to assess how…
Sponsor: BioNTech SE
NCT ID: NCT06340568
Sites in South Dakota: - Sanford Cancer Center — Sioux Falls, South Dakota
Phase 3 Recruiting Industry
This study is designed to assess efficacy and safety of T-DXd adjuvant therapy, with or without radiotherapy, post-surgery in anticancer treatment naïve (including neoadjuvant therapy) endometrial cancer with various HER2 expression levels.
Sponsor: Daiichi Sankyo
NCT ID: NCT07022483
Sites in South Dakota: - Avera Medical Group Gynecologic Oncology Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in South Dakota: - Rapid City Regional Hospital — Rapid City, South Dakota
- Sanford Cancer Center Oncology Clinic — Sioux Falls, South Dakota
- Sanford USD Medical Center - Sioux Falls — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
This is an open label Phase 2 study to evaluate the efficacy and safety of ACR-368 as monotherapy or with ultra-low dose gemcitabine (ULDG) sensitization in participants with endometrial cancer.
Sponsor: Acrivon Therapeutics
NCT ID: NCT05548296
Sites in South Dakota: - Sanford Health — Sioux Falls, South Dakota
Phase 1, Phase 2 Recruiting Industry
A Study of Emi-Le in Participants with Solid Tumors
Sponsor: Day One Biopharmaceuticals, Inc.
NCT ID: NCT05377996
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
This is a Phase 2, multicenter, open-label, single-arm study to evaluate the efficacy and safety of sapanisertib and serabelisib (PIKTOR) with paclitaxel in participants with advanced or recurrent endometrial cancer.
Sponsor: Faeth Therapeutics
NCT ID: NCT06463028
Sites in South Dakota: - Avera Cancer Institute — Sioux Falls, South Dakota
Phase 2 Recruiting Industry
The purpose of this study is to investigate the efficacy and safety of the lifileucel regimen in participants with previously treated endometrial cancer.
Sponsor: Iovance Biotherapeutics, Inc.
NCT ID: NCT06481592
Sites in South Dakota: - Avera Medical Group Oncology — Sioux Falls, South Dakota
Recruiting Academic/Other
The purpose of this study is to characterize the breadth of molecular features present in participants receiving care within a large, integrated, community-based healthcare system. Through comprehensive genomic profiling, investigators aim…
Sponsor: Avera McKennan Hospital & University Health Center
NCT ID: NCT05142033
Sites in South Dakota: - Avera Cancer Institute - Aberdeen — Aberdeen, South Dakota
- Avera Cancer Institute - Mitchell — Mitchell, South Dakota
- Avera Cancer Institute - Pierre — Pierre, South Dakota
- Avera Cancer Institute — Sioux Falls, South Dakota
- Avera Cancer Institute - Yankton — Yankton, South Dakota